KRAS and familial pancreatic carcinoma: In addition to ctDNA, exoDNA has also been shown to have prognostic value, with KRAS mutant allele fraction (MAF) being associated with progression-free survival (PFS) and overall-survival (OS) in pancreatic cancer [32].